IPSEN PHARMA

In News

Ipsen scuttles liver disease candidates from Albireo acquisition - Fierce Biotech

Fierce Biotech - May 06, 2026

Ipsen to withdraw cancer drug acquired in buyout due to safety concerns - BioPharma Dive

BioPharma Dive - Mar 09, 2026

Ipsen showcases transformative potential of early immuno-oncology pipeline at AACR - Ipsen

Ipsen - Mar 18, 2026

Ipsen backs away from cancer med Tazverik after safety signals emerge in lymphoma trial - Fierce Pharma

Fierce Pharma - Mar 09, 2026

Ipsen delivers strong results in 2025, driven by solid execution across all therapeutic areas, and provides 2026 guidance - Yahoo Finance

Yahoo Finance - Feb 11, 2026

Ipsen delivers strong sales in the first quarter of 2026 and confirms its full-year guidance - GlobeNewswire

GlobeNewswire - Apr 23, 2026

Quotient Sciences, Ipsen Extend Commercial Manufacturing Pact - Contract Pharma

Contract Pharma - Feb 26, 2026

Ipsen S.A. publishes its 2025 Consolidated Financial Statements - Ipsen

Ipsen - Feb 19, 2026

Ipsen's hopes for next-gen rare disease drug dashed by pivotal phase 2 fail - Fierce Biotech

Fierce Biotech - Dec 19, 2025

Update: Ipsen voluntarily withdraws Tazverik® (tazemetostat) in follicular lymphoma and epithelioid sarcoma - Yahoo Finance

Yahoo Finance - Mar 09, 2026

CDMO Quotient extends Ipsen supply pact for rare disease drug Sohonos - Fierce Pharma

Fierce Pharma - Mar 02, 2026

Strong Q1 2026 sales growth, marking a solid start to the year - Ipsen

Ipsen - Apr 23, 2026

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment